The Arab Drug Company (EGX: ADCI)
Egypt
· Delayed Price · Currency is EGP 103.21
0.00 (0.00%)
At close: Nov 20, 2024
The Arab Drug Company Income Statement
Financials in millions EGP. Fiscal year is July - June.
Millions EGP. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2015 |
| Operating Revenue | 826.74 | 784.65 | 630.1 | 503.79 | 537.05 | 520.8 | Upgrade
|
| Other Revenue | 0.88 | 0.88 | 3.64 | 1.25 | - | - | Upgrade
|
| Revenue | 827.61 | 785.52 | 633.73 | 505.04 | 537.05 | 520.8 | Upgrade
|
| Revenue Growth (YoY) | 23.34% | 23.95% | 25.48% | -5.96% | 3.12% | 19.35% | Upgrade
|
| Cost of Revenue | 532.69 | 519.53 | 409.39 | 319.61 | 306.74 | 307.12 | Upgrade
|
| Gross Profit | 294.93 | 265.99 | 224.35 | 185.43 | 230.3 | 213.68 | Upgrade
|
| Selling, General & Admin | 102.7 | 98.16 | 98.83 | 81.02 | 81.78 | 73.06 | Upgrade
|
| Other Operating Expenses | 62.59 | 49.73 | 28.44 | 13.64 | 26.33 | 23.34 | Upgrade
|
| Operating Expenses | 165.29 | 147.89 | 127.27 | 94.66 | 108.11 | 96.39 | Upgrade
|
| Operating Income | 129.64 | 118.1 | 97.08 | 90.77 | 122.2 | 117.29 | Upgrade
|
| Interest Expense | -32.7 | -23.09 | -2.32 | -0.95 | -0.04 | - | Upgrade
|
| Interest & Investment Income | 36.73 | 27.98 | 1.11 | 1.67 | 4.4 | 1.93 | Upgrade
|
| Currency Exchange Gain (Loss) | 6.11 | 6.24 | 9.75 | 3.24 | 0.09 | 0.48 | Upgrade
|
| Other Non Operating Income (Expenses) | 4.09 | 3.17 | 1.11 | 3.05 | 4.29 | - | Upgrade
|
| EBT Excluding Unusual Items | 143.88 | 132.4 | 106.73 | 97.78 | 130.94 | 119.69 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.18 | 0.18 | - | 0.51 | 0.01 | - | Upgrade
|
| Pretax Income | 144.06 | 132.58 | 106.73 | 98.3 | 130.96 | 119.69 | Upgrade
|
| Income Tax Expense | 32.34 | 29.75 | 23.96 | 22 | 29.55 | 26.89 | Upgrade
|
| Net Income | 111.72 | 102.82 | 82.77 | 76.3 | 101.41 | 92.8 | Upgrade
|
| Preferred Dividends & Other Adjustments | 14.48 | 14.48 | 11.64 | - | - | - | Upgrade
|
| Net Income to Common | 97.24 | 88.35 | 71.13 | 76.3 | 101.41 | 92.8 | Upgrade
|
| Net Income Growth | 35.43% | 24.23% | 8.48% | -24.76% | 9.28% | 115.30% | Upgrade
|
| Shares Outstanding (Basic) | - | 6 | 6 | 7 | 7 | 7 | Upgrade
|
| Shares Outstanding (Diluted) | - | 6 | 6 | 7 | 7 | 7 | Upgrade
|
| Shares Change (YoY) | - | - | -11.45% | -2.11% | -6.76% | -6.65% | Upgrade
|
| EPS (Basic) | - | 14.72 | 11.85 | 11.26 | 14.65 | 12.50 | Upgrade
|
| EPS (Diluted) | - | 14.72 | 11.85 | 11.26 | 14.65 | 12.50 | Upgrade
|
| EPS Growth | - | 24.21% | 5.28% | -23.14% | 17.20% | 130.63% | Upgrade
|
| Free Cash Flow | -120.77 | -83.19 | 24.33 | -57.04 | 7.71 | 70.7 | Upgrade
|
| Free Cash Flow Per Share | - | -13.86 | 4.05 | -8.42 | 1.11 | 9.52 | Upgrade
|
| Dividend Per Share | 8.350 | 8.350 | 4.500 | 4.800 | 5.000 | 2.500 | Upgrade
|
| Dividend Growth | 85.56% | 85.56% | -6.25% | -4.00% | 100.00% | -19.35% | Upgrade
|
| Gross Margin | 35.64% | 33.86% | 35.40% | 36.72% | 42.88% | 41.03% | Upgrade
|
| Operating Margin | 15.66% | 15.03% | 15.32% | 17.97% | 22.75% | 22.52% | Upgrade
|
| Profit Margin | 11.75% | 11.25% | 11.22% | 15.11% | 18.88% | 17.82% | Upgrade
|
| Free Cash Flow Margin | -14.59% | -10.59% | 3.84% | -11.30% | 1.44% | 13.58% | Upgrade
|
| EBITDA | 139.78 | 128.13 | 99.46 | 100.17 | 130.01 | 118.02 | Upgrade
|
| EBITDA Margin | 16.89% | 16.31% | 15.69% | 19.83% | 24.21% | 22.66% | Upgrade
|
| D&A For EBITDA | 10.14 | 10.03 | 2.38 | 9.39 | 7.81 | 0.73 | Upgrade
|
| EBIT | 129.64 | 118.1 | 97.08 | 90.77 | 122.2 | 117.29 | Upgrade
|
| EBIT Margin | 15.66% | 15.03% | 15.32% | 17.97% | 22.75% | 22.52% | Upgrade
|
| Effective Tax Rate | 22.45% | 22.44% | 22.45% | 22.38% | 22.56% | 22.47% | Upgrade
|
| Revenue as Reported | 827.61 | 785.52 | 633.73 | 505.04 | 537.05 | 521.07 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.